Skip to main content
Premium Trial:

Request an Annual Quote

Response in Kids Reported

Moderna's SARS-CoV-2 vaccine prompts a strong immune response among children between the ages of 6 and 11 years old, the New York Times reports.

The US Food and Drug Administration approved Moderna's vaccine, dubbed Spikevax, for adults 18 years old and older in February, and a booster dose and a third full dose of the vaccine are available under an emergency use authorization. But currently, only Pfizer's SARS-CoV-2 vaccine is authorized for children and teens, and no vaccine is available for children under the age of 5.

Now in a study appearing in the New England Journal of Medicine, researchers from Moderna and elsewhere report data from an ongoing phase 2/3 trial that indicates that two doses of the Moderna vaccine — half the dose given to an adult — could induce immune responses in children between 6 and 11 years old. Those antibody levels, the Times notes, were slightly higher than what is generated in young adults.

The Times adds that Moderna asked the FDA on Monday to authorize the use of its vaccine in this age group. The company previously asked the agency for an EUA for its vaccine for very small children between 6 months and 6 years old and for adolescents. The Times notes that while other countries have allowed the Moderna vaccine for adolescents, the FDA review appears to have stalled.

Filed under

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.